GlassScriptPhysician profile
Jennifer Wheeley
NPI 1164030896
$4,154.78
in general payments reported to CMS, 2019-2025
24 companies · $2,034 in 2025
The $2,034 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $22.28 · 2022: $79.76 · 2023: $1,442 · 2024: $577 · 2025: $2,034.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,755 · Travel and Lodging: $1,001 · Education: $297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,754.89 |
| Travel and Lodging | $1,000.95 |
| Education | $296.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $1,394.02 | 2022-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Janssen Biotech, INC. | $545.48 | 2023-2025 | Rybrevant, Carvykti, Erleada |
| E.R. Squibb & Sons, L.L.C. | $340.25 | 2022-2025 | Opdivo, Opdualag |
| Daiichi Sankyo INC. | $323.34 | 2024-2025 | Enhertu, Datroway |
| Astrazeneca Pharmaceuticals LP | $232.44 | 2023-2025 | Imfinzi |
| Gilead Sciences, INC. | $169.11 | 2025 | Trodelvy |
| Lilly USA, LLC | $169.07 | 2024-2025 | Verzenio, Jaypirca, Retevmo |
| Abbvie INC. | $151.25 | 2025 | |
| Genentech, INC. | $145.53 | 2024 | Phesgo, Tecentriq, Avastin |
| Jazz Pharmaceuticals INC. | $101.40 | 2025 | |
| Mirati Therapeutics, INC. | $98.42 | 2023-2024 | Krazati |
| Genentech USA, INC. | $74.67 | 2023-2024 | Tecentriq, Tecentriq Hybreza |
| Caris Mpi, INC. | $70.52 | 2025 | Mi Cancer Seek |
| Celgene Corporation | $58.12 | 2023 | Pomalyst |
| Genzyme Corporation | $42.69 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $42.01 | 2025 | Zoladex, Xermelo |
| Regeneron Healthcare Solutions, INC. | $35.33 | 2023-2025 | Libtayo |
| Deciphera Pharmaceuticals INC. | $32.68 | 2025 | Romvimza, Qinlock |
| Exelixis INC. | $26.17 | 2023 | Cabometyx |
| Servier Pharmaceuticals LLC | $25.51 | 2024 | |
| Eisai INC. | $20.53 | 2023 | |
| Novartis Pharmaceuticals Corporation | $19.34 | 2025 | |
| Springworks Therapeutics, INC. | $18.87 | 2024 | Ogsiveo |
| Adc Therapeutics America, INC. | $18.03 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Wheeley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.